Investors

Company snapshot

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA‐DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), a first‐in‐class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been approved by the European Commission for treating adults with EPP.

Based in Melbourne, Australia, CLINUVEL has operations in Europe, the US and Singapore.

 

 

 

Facts

ASX Listed

2001

 

Shares on Issue

47,725,227

 

Conditional performance rights

1,907,660

 

52 week price range (01/02/2017)

$2.86 - $9.19

 

Market cap (01/02/2017)

A$371.78m

Locations

Melbourne, Australia

Company headquarters

 

Zug, Switzerland

European operational office

 

New York, USA

US operational office

 

Leatherhead, UK

UK operational office

 

Singapore

Asian operational office

 

www.clinuvel.com

 

Stock listings

ASX

CUV

 

Xetra-DAX

UR9

 

Level 1 ADR

CLVLY

Finances

Cash/assets at bank (31/12/2016)

A$19.550m

 

Monthly spend rate (av. Q4 '14 - Q3 ’15)

A$0.65m

Products

SCENESSE® (afamelanotide 16mg implant)

First-in-class photoprotective and repigmentation drug with EMA approval for rare diseae EPP. Phase IIb trial ongoing in Singapore for vitiligo

 

CUV9900

Alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogues in early development

 

VLRX001

 

People

Stanley McLiesh

Non-Executive Chair

 

Dr Philippe Wolgen

CEO, Director

 

Brenda Shanahan

Non-Executive Director

 

Elie Ishag

Non-Executive Director

 

Willem Blijdorp

Non-Executive Director

 

Dr Dennis Wright

Acting Chief Scientific Officer

 

Darren Keamy

CFO, Company Secretary

Contact

General

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Investors

This email address is being protected from spambots. You need JavaScript enabled to view it.

Last updated: 01 February 2017

Quick Links